Abstract: NOVELTY - Peritoneal fibrosis is prevented using an agent for modulating MEK 1 and/or MEK 2 activity. USE - For preventing or treating fibrosis of the peritoneal membrane, including peritoneal opacification, tanned peritoneal syndrome, mural fibrosis and sclerosing peritonitis syndrome, which results from long-term peritoneal dialysis. ADVANTAGE - An effective treatment for preventing progressive loss of peritoneal dialytic capacity in patients undergoing peritoneal dialysis. DETAILED DESCRIPTION - A composition comprising an agent for modulating MEK 1 and/or MEK 2 activity is used to prepare a medicament for preventing or treating peritoneal fibrosis. INDEPENDENT CLAIMS are also included for the following: (1) Method for identifying therapeutic agents suitable for treating peritoneal fibrosis, comprising contacting the compound to be analyzed with the polynucleotide and/or polypeptide MEK 1 and/or MEK 2 and then detecting the bond between the compound and polynucleotide and/or polypeptide; (2) Method for identifying therapeutic agents suitable for treating peritoneal fibrosis, comprising measuring the activity of MEK 1 and/or MEK 2 at a given concentration of the compound to be analyzed or in the absence of this compound, and measuring the same activity at different concentration of this compound; (3) Method for identifying therapeutic agents suitable for treating peritoneal fibrosis, comprising measuring the activity of MEK 1 and/or MEK 2 at a given concentration of the compound to be analyzed, and measuring the same activity in the presence of a compound which is known to modulate MEK 1 or MEK 2 activity; and (4) Method for obtaining useful data for the diagnosis and/or prognosis of peritoneal fibrosis, by determining the expression of MEK 1 and/or MEK 2 in a sample taken from a mammal and the comparing these MEK 1 and/or MEK 2 expression values with those in a healthy or ill mammal.
Medicament for preventing peritoneal fibrosis due to long term peritoneal dialysis, comprises MEK 1 or 2 activity modulating agent / M. A., DEL POZO BARRIUSO; M., LOPEZ CABRERA; Strippoli, Raffaele. - (2008).
Medicament for preventing peritoneal fibrosis due to long term peritoneal dialysis, comprises MEK 1 or 2 activity modulating agent
STRIPPOLI, RAFFAELE
2008
Abstract
Abstract: NOVELTY - Peritoneal fibrosis is prevented using an agent for modulating MEK 1 and/or MEK 2 activity. USE - For preventing or treating fibrosis of the peritoneal membrane, including peritoneal opacification, tanned peritoneal syndrome, mural fibrosis and sclerosing peritonitis syndrome, which results from long-term peritoneal dialysis. ADVANTAGE - An effective treatment for preventing progressive loss of peritoneal dialytic capacity in patients undergoing peritoneal dialysis. DETAILED DESCRIPTION - A composition comprising an agent for modulating MEK 1 and/or MEK 2 activity is used to prepare a medicament for preventing or treating peritoneal fibrosis. INDEPENDENT CLAIMS are also included for the following: (1) Method for identifying therapeutic agents suitable for treating peritoneal fibrosis, comprising contacting the compound to be analyzed with the polynucleotide and/or polypeptide MEK 1 and/or MEK 2 and then detecting the bond between the compound and polynucleotide and/or polypeptide; (2) Method for identifying therapeutic agents suitable for treating peritoneal fibrosis, comprising measuring the activity of MEK 1 and/or MEK 2 at a given concentration of the compound to be analyzed or in the absence of this compound, and measuring the same activity at different concentration of this compound; (3) Method for identifying therapeutic agents suitable for treating peritoneal fibrosis, comprising measuring the activity of MEK 1 and/or MEK 2 at a given concentration of the compound to be analyzed, and measuring the same activity in the presence of a compound which is known to modulate MEK 1 or MEK 2 activity; and (4) Method for obtaining useful data for the diagnosis and/or prognosis of peritoneal fibrosis, by determining the expression of MEK 1 and/or MEK 2 in a sample taken from a mammal and the comparing these MEK 1 and/or MEK 2 expression values with those in a healthy or ill mammal.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
